top of page
SUMMARY
HALOVAX™
– NANOCLAY VACCINE PATCH FOR SUSTAINED ANTIGEN DELIVERY
NEEDLE-FREE. THERMOSTABLE.
COMBAT-READY.
HaloVax™ is a transdermal patch platform that delivers sustained-release vaccines using halloysite nanotube (HNT) nanocarriers embedded in a biodegradable matrix. Developed for the Department of Defense, this platform enables 14+ days of antigen release, eliminating cold-chain requirements and reducing the number of injections needed for effective immunization.
GET INVOLVED
No syringes
Room-temperature stable
Multi-week immune priming
Designed for HIV, flu, malaria, & future biodefense pathogens
HOW IT WORKS
Halloysite nanotubes (HNTs) are loaded with recombinant antigen (such as gp140 for HIV).
Embedded in a gelatin-glycerin film that softens on skin contact.
Patch adheres to skin, delivering antigen over 14–21 days.
Flexible for dermal, nasal, or mucosal routes.
KEY FEATURES
FEATURE
DESCRIPTION
Sustained Delivery
Target Antigen
Matrix Material
Nanocarrier
Patch Size
Dose
Temperature Stability
Regulatory Targets
TRL Level
≥80% release over 14 days (in vitro)
HIV-1 gp140 in initial application (can also be adapted for other pathogens)
Biodegradable gelatin/glycerin
Halloysite clay nanotubes (15–20 nm lumen)
~2 cm², flexible backing
~50–200 µg antigen per patch
No refrigeration required
FDA IND-ready, 21 CFR 210/211/820 aligned
TRL 4–5 (Phase I) progressing to TRL 7 (Phase II)
DEFENSE-READY & GLOBAL HEALTH IMPACT
WARFIGHTER USE CASES
Vaccination in austere environments, forward-operating bases, ships, submarines
COMBATANT COMMANDS
AFRICOM, SOUTHCOM
HIV, malaria, flu vaccination in deployed personnel
CIVILIAN HEALTH SETTINGS
Pediatric, rural, or needle-averse populations; global pandemic readiness
NASAL / MUCOSAL ADAPTATION
Ongoing studies for intranasal delivery with local immunity activation
PHASE I RESULTS
RELEASE PROFILE
80% antigen sustained release in PBS over 14 days
PATCH CASTING
Optimized 2–3 layer matrix for retention and skin adhesion
PROTEIN INTEGRITY
Verified via SDS-PAGE and ELISA
MOUSE PILOT STUDIES
BALB/c immunogenicity testing with gp140 + adjuvant
TECHNOLOGY INNOVATION
HNT NANOCARRIERS
Tunable lumen for protein encapsulation and time-controlled release
BIODEGRADABLE MATRIX
Gelatin-glycerin composite with excellent retention and safe absorption
SCALABLE MANUFACTURING
Patch casting with standard drying and sterilization processes
NO COLD
CHAIN
Eliminates 70%+ of global vaccine logistics burden
PROJECT TEAM
DR. YURI
M. LVOV
Inventor of HNT biomedical carriers, 300+ publications
DR. KONSTANTIN DOLGAN
Mechanical engineer and product development lead
DR. MAHDI
SALEH
Formulation and preclinical design
ONEGA
ULANOVA
Regulatory & commercialization strategy
GRAPHENO LLC
+
LOUISIANA TECH UNIVERSITY
+
MHRP
(planned Phase II partner)
ROADMAP
PHASE I
COMPLETED
PHASE II
PROPOSED
PHASE III
PLANNED
Protein-HNT loading, matrix optimization, in vitro release
Patch fabrication at lab scale (200 prototypes)
Regulatory landscape mapping (IND enabling requirements)
Mouse immunogenicity studies
Optimization of gp140 dosage and adjuvant delivery
5000+ patch production (GMP-aligned pilot line)
IACUC, ACURO, and FDA consults
Large animal validation
IND-enabling data package
Dual path to DoD and global health deployment
DOWNLOADS
Technical Summary PDF
SBIR Abstract / Quad Chart
Regulatory Readiness Matrix
Pilot Collaboration Request Form
GET INVOLVED
QD LABS IS CURRENTLY SEEKING PARTNERS FOR THE NEXT STEP IN HALOVAX™ DEVELOPMENT:
Clinical partners
(e.g. MHRP, NIH, BARDA, WHO)
Investors interested in pandemic readiness, HIV prevention, or dual-use biotech
Manufacturers of dissolvable patch materials
DoD operational testing sites
IF YOU ARE INTERESTED IN PARTNERING, PLEASE REACH OUT
— WE ARE EAGER TO WORK WITH YOU!
Request Phase II Briefing
Let’s Collaborate on the Future of Materials and Defense Tech
Quantum Diffusion Corp
419 Dan Reneau Dr. Ruston, LA 71270
bottom of page